Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allen Chung

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Biomedicines|February 26, 2020
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung AdenocarcinomaPing-Chih Hsu, Chih-Wei Wang, Scott Chih-Hsi Kuo, et al.
Thoracic Cancer|January 27, 2024
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancerLi-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, et al.
The Journal of Clinical Investigation|January 29, 2026
ADAMTS7 promotes smooth muscle foam cell expansion in atherosclerosisAllen Chung, Lauren E Fries, Hyun-Kyung Chang, et al.
International Journal of Medical Sciences|November 28, 2022
Comparison of Clinical Characteristics and Outcomes of Hospitalized Patients Infected with the D614G Strain or Alpha Variant of COVID-19 in Taiwan: A Multi-Center Cohort StudyAllen Chung-Cheng Huang, Shu-Min Lin, Tzu-Hsuan Chiu, et al.
Oncology Letters|March 12, 2025
Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasisChen-Chuan Hsu, Li-Chung Chiu, How-Wen Ko, et al.
Oncology and Therapy|May 15, 2021
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination TherapyChin-Chou Wang, Li-Chung Chiu, Pi-Hung Tung, et al.
BMC Cancer|March 25, 2021
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failedChih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, et al.
Biomedical Journal|November 22, 2022
Clinical and laboratory predictors for disease progression in patients with COVID-19: A multi-center cohort studyShu-Min Lin, Allen Chung-Cheng Huang, Tzu-Hsuan Chiu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 15, 2023
Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort studyShu-Min Lin, Chung-Shu Lee, Allen Chung-Cheng Huang, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational StudyPing-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Biomedicines|February 26, 2020
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung AdenocarcinomaPing-Chih Hsu, Chih-Wei Wang, Scott Chih-Hsi Kuo, et al.
Thoracic Cancer|January 27, 2024
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancerLi-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang, et al.
The Journal of Clinical Investigation|January 29, 2026
ADAMTS7 promotes smooth muscle foam cell expansion in atherosclerosisAllen Chung, Lauren E Fries, Hyun-Kyung Chang, et al.
International Journal of Medical Sciences|November 28, 2022
Comparison of Clinical Characteristics and Outcomes of Hospitalized Patients Infected with the D614G Strain or Alpha Variant of COVID-19 in Taiwan: A Multi-Center Cohort StudyAllen Chung-Cheng Huang, Shu-Min Lin, Tzu-Hsuan Chiu, et al.
Oncology Letters|March 12, 2025
Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasisChen-Chuan Hsu, Li-Chung Chiu, How-Wen Ko, et al.
Oncology and Therapy|May 15, 2021
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination TherapyChin-Chou Wang, Li-Chung Chiu, Pi-Hung Tung, et al.
BMC Cancer|March 25, 2021
A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failedChih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, et al.
Biomedical Journal|November 22, 2022
Clinical and laboratory predictors for disease progression in patients with COVID-19: A multi-center cohort studyShu-Min Lin, Allen Chung-Cheng Huang, Tzu-Hsuan Chiu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 15, 2023
Effects of dexamethasone use on viral clearance among patients with COVID-19: a multicenter cohort studyShu-Min Lin, Chung-Shu Lee, Allen Chung-Cheng Huang, et al.
Pharmaceuticals (Basel, Switzerland)|October 29, 2020
The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational StudyPing-Chih Hsu, Chun-Yao Huang, Chin-Chou Wang, et al.
Pageof 4